Costunolide reduces glycolysis-associated activation of hepatic stellate cells via inhibition of hexokinase-2.

Background: Hepatic stellate cell (HSC) activation is a central event during hepatic fibrosis. Aerobic glycolysis is one of its metabolic hallmarks. Blocking glycolysis is a novel therapeutic option for liver fibrosis.